It has been reported that, at the early stage of SARS-CoV-2 infection, increased serum levels of CCL5 were observed in patients with mild COVID-19 symptoms compared to severe patients, suggesting that CCL5 may protect against viral infection, where virus-specific CD8+ T cells respond to the removal of the virus before lung inflammation occurs (79). This evidence concerns the gene CD8A and COVID-19.